GSK (GSK) has agreed to buy US-listed biotech RAPT Therapeutics (US: RAPT) for $58 a share, valuing the company at about $2.2bn (拢1.6bn), as it bolsters its respiratory and immunology pipeline.
The deal brings ozureprubart, a long-acting antibody for the prevention of severe food allergy reactions, and currently in phase II trials, into GSK鈥檚 pipeline. The potential advantage of ozureprubart is that dosing could be done every 12 weeks, rather than every two to four weeks for existing therapies. GSK said the drug could also help patients currently ineligible for standard treatment.
Phase IIb data is due in 2027, with phase III studies planned in adults and children. When potential milestone payments are excluded, GSK鈥檚 upfront investment is estimated at $1.9bn.




